EcoDrugPlus

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSOKIG00005049848
Gene Symbol: PSMB6
3 Cross references
179 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSOKIG00005049816
Gene Symbol: PSMB6
3 Cross references
180 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSOKIG00005048400
Gene Symbol: PSMB7
1 Cross references
213 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSOKIG00005022436
Gene Symbol: PSMB9A
1 Cross references
200 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSOKIG00005024834
Gene Symbol: PSMD2
3 Cross references
215 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSOKIG00005031858
Gene Symbol: PSMD2
3 Cross references
216 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4

Ensembl ID : ENSOKIG00005027823
Gene Symbol: PSMD4
3 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4

Ensembl ID : ENSOKIG00005022033
Gene Symbol: PSMD4
1 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSOKIG00005022149
Gene Symbol: PSMC1
3 Cross references
87 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSOKIG00005037661
Gene Symbol: PSMC2
1 Cross references
230 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSOKIG00005044323
Gene Symbol: PSMC2
3 Cross references
230 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSOKIG00005010496
Gene Symbol: PSMC3
1 Cross references
221 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).